Development of Artificial Intelligence-based Machine Learning Models for Predicting Survival In Hormone-Receptor-Positive/HER2-Negative Early Breast Cancer undergoing Neoadjuvant Chemotherapy

被引：0
|
作者：
Mastrantoni, Luca
Garufi, Giovanna
Maliziola, Noemi
Di Monte, Elena
Arcuri, Giorgia
Frescura, Valentina
Rotondi, Angelachiara
Giordano, Giulia
Carbognin, Luisa
Fabi, Alessandra
Paris, Ida
Franceschini, Gianluca
Orlandi, Armando
Palazzo, Antonella
Scambia, Giovanni
Tortora, Giampaolo
Bria, Emilio
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-01-14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-01-14
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Artificial intelligence (AI)-based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study
    Mastrantoni, Luca
    Garufi, Giovanna
    Maliziola, Noemi
    Di Monte, Elena
    Arcuri, Giorgia
    Frescura, Valentina
    Rotondi, Angelachiara
    Giordano, Giulia
    Carbognin, Luisa
    Fabi, Alessandra
    Paris, Ida
    Marazzi, Fabio
    Antonio, Franco
    Franceschini, Gianluca
    Orlandi, Armando
    Palazzo, Antonella
    Scambia, Giovanni
    Tortora, Giampaolo
    Bria, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT)
    Mastrantoni, L.
    Garufi, G.
    Di Monte, E.
    Arcuri, G.
    Frescura, V.
    Maliziola, N.
    Rotondi, A.
    Giordano, G.
    Carbognin, L.
    Fabi, A.
    Paris, I.
    Franceschini, G.
    Orlandi, A.
    Palazzo, A.
    Puglisi, F.
    Dieci, M. V.
    Milella, M.
    Scambia, G.
    Tortora, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S294 - S294
  • [3] Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
    Torrisi, Rosalba
    Marrazzo, Emilia
    Agostinetto, Elisa
    De Sanctis, Rita
    Losurdo, Agnese
    Masci, Giovanna
    Tinterri, Corrado
    Santoro, Armando
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
  • [4] Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
    Matikas, A.
    Lovrot, J.
    Ramberg, A.
    Eriksson, M.
    Lindsten, T.
    Lekberg, T.
    Hedenfalk, I.
    Loman, N.
    Bergh, J.
    Erlandsson, A.
    Hatschek, T.
    Foukakis, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer
    Niu, Nan
    Xue, Jinqi
    Qiu, Fang
    Chen, Guanglei
    Gu, Xi
    He, Guijin
    Cao, Shuo
    Yu, Xiaopeng
    Xu, Yongqing
    Yin, Jianqiao
    Han, Sijia
    Han, Ye
    Tang, Meiyue
    Zhao, Yafei
    Zheng, Ran
    Zheng, Xinyu
    Xu, Hong
    Liu, Caigang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast cancer
    Lopez, M.
    Di Lauro, L.
    Viola, G.
    Foggi, P.
    Conti, F.
    Corsetti, S.
    Sergi, D.
    Botti, C.
    Di Filippo, F.
    Vici, P.
    CLINICA TERAPEUTICA, 2009, 160 (06): : 481 - 488
  • [7] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [8] Methods for selection of neoadjuvant treatment with chemotherapy for patients with hormone receptor-positive and HER2-negative with early breast cancer.
    Gasol Cudos, Ariadna
    Morales Murillo, Serafin
    Tuset Der-abrain, Noemi
    Arbones Cid, Laura
    Morera Morillo, Ester
    Vilardell, Felip
    Sanchez Guzman, Douglas
    Canosa Morales, Carles
    Mele Olive, Jordi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
  • [10] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
12345